ARA-290 10MG – 연구용 펩타이드

ARA-290은 염증 조절, 조직 보호, 세포 스트레스 반응 연구에서 연구되는 합성 펩타이드입니다. 표적 펩타이드 구조 덕분에 신경학적, 대사적, 재생 연구 프로그램에서 주목받고 있습니다.

우리의 ARA-290 10mg 는 high purity and precise peptide composition안정적이고 반복 가능한 연구 결과를 보장합니다. 각 바이알은 운송 및 보관 중 습기, 빛, 온도 변화로부터 보호할 수 있도록 신중하게 포장되어 있습니다.

ARA-290은 염증, 신경생물학, 조직 보호 연구에 관여하는 첨단 연구 기관 및 유통업체에 적합합니다.

ARA-290 is a peptide derivative of erythropoietin (EPO) that has shown significant promise in decreasing inflammatory pathways and enhancing repair mechanisms through its action on the innate repair receptors. This peptide, also known as cibinetide, has demonstrated various beneficial effects in clinical research, including reducing HbA1c levels, improving cholesterol profiles, modulating neuropathic pain, and accelerating wound healing. Product Usage: ARA-290 is strictly intended for use as a research chemical. It is designated for in vitro testing and laboratory experimentation only. Introduction into humans or animals is prohibited by law, and it should only be handled by licensed, qualified professionals. This product is not approved as a drug, food, or cosmetic. Introduction ARA-290 is a synthetic variant of the helix beta domain of erythropoietin, designed to harness the neuroprotective and analgesic effects of EPO without promoting red blood cell production. This peptide has progressed through phase II clinical trials and is preparing for phase III trials targeting several applications, including diabetes management and autoimmune sarcoidosis. Comprehensive Overview and Research Applications Neuroprotection and Neuropathic Pain ARA-290 has emerged as a potent neuroprotective agent, offering significant benefits in diabetic neuropathy and potentially other neurodegenerative conditions. Unlike traditional erythropoietin, which can lead to excessive red blood cell production, ARA-290 targets only the protective pathways, alleviating pain without the associated hematologic risks. Cardiovascular and Vascular Health ARA-290’s effects extend to cardiovascular health, particularly in protecting against retinal ischemia—a common cause of blindness. By safeguarding endothelial cells and promoting their regeneration, ARA-290 could significantly reduce the burden of vascular diseases. Additionally, its ability to enhance the survival and function of endothelial colony-forming cells could revolutionize treatments for vascular injuries and ischemic conditions. Inflammation and Immune Modulation The peptide’s role in reducing inflammatory cytokines and modulating the immune response has implications for transplant medicine, particularly in the survival of transplanted islet cells for diabetes treatment. By inhibiting macrophage activation and cytokine production, ARA-290 could improve the outcomes of cellular transplants and reduce the incidence of rejection. Tissue Protection and Wound Healing ARA-290 has shown potential in speeding up the wound healing process, particularly in chronic conditions like diabetes, where slow healing leads to complications. Its ability to stimulate tissue repair and reduce scarring could make it a valuable asset in managing and treating skin injuries and surgical wounds.